The key objectives of this grant are to mentor junior investigators to conduct hypothesis-driven research projects related to colorectal cancer (CRC) prevention. I will utilize my research program and its areas of focus to achieve this objective that will involve mentoring investigators in the following areas: 1) an interventional chemoprevention trial;2) the study of prognostic and predictive biomarkers, inclusive of epidemiological factors, in relation to cancer outcomes in adjuvant treatment trials;and 3) novel therapeutic strategies for chemoprevention with a focus on apoptotic signaling pathways as molecular targets. These projects represent significant opportunities to conduct timely and clinically important research that builds upon a successful program that utilizes a high risk study population and a unique tissue resource and database from a cancer cooperative group. My overall mentoring objectives are to improve the research knowledge, skills, professional maturity, and academic productivity of junior investigators that will enable them to become independent investigators and future leaders in cancer prevention and control. The K05 grant will also serve another important objective of providing increased protected time for the principal investigator to pursue and expand his ongoing translational research efforts in colorectal cancer that can lead to programmatic expansion and additional extramural funding. Increased protected time will also facilitate my commitment to mentoring and enable me to continue to make important contributions that serve to advance the field of cancer prevention. The end product of these efforts is the potential to reduce cancer incidence and recurrence, thus eliminating suffering related to colorectal cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Scientist Award (K05)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Sweetser, Seth; Jones, Andrea; Smyrk, Thomas C et al. (2016) Sessile Serrated Polyps are Precursors of Colon Carcinomas With Deficient DNA Mismatch Repair. Clin Gastroenterol Hepatol 14:1056-9
Lee, Adam M; Shi, Qian; Alberts, Steven R et al. (2016) Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 26:133-7
Sinicrope, Frank A; Okamoto, Koichi; Kasi, Pashtoon M et al. (2016) Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol 14:651-8
Zaanan, Aziz; Park, Jae Myung; Tougeron, David et al. (2015) Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. Int J Cancer 137:1498-502
Campbell, Peter T; Newton, Christina C; Newcomb, Polly A et al. (2015) Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev 24:1229-38
Sinicrope, Frank A; Mahoney, Michelle R; Yoon, Harry H et al. (2015) Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res 21:5294-304
Phipps, Amanda I; Limburg, Paul J; Baron, John A et al. (2015) Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 148:77-87.e2
Sinicrope, Frank A; Shi, Qian; Smyrk, Thomas C et al. (2015) Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148:88-99
Yoon, Harry H; Shi, Qian; Alberts, Steven R et al. (2015) Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst 107:
Zaanan, Aziz; Okamoto, Koichi; Kawakami, Hisato et al. (2015) The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. J Biol Chem 290:23838-49

Showing the most recent 10 out of 50 publications